Jun 24 |
Lilly’s tirzepatide reduces OSA severity in Phase III clinical trials
|
Jun 24 |
Broadcom, Eli Lilly and Trump Media rise premarket; Under Armour falls
|
Jun 23 |
Did Eli Lilly and Company (LLY) Achieve Its 10th Consecutive Year of Dividend Growth?
|
Jun 23 |
Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
|
Jun 22 |
GLP-1 drugs linked to reduced dementia risk: study
|
Jun 22 |
ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug
|
Jun 21 |
Lilly weight loss drug tirzepatide meets primary endpoint in sleep apnea study
|
Jun 21 |
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
|
Jun 21 |
Eli Lilly’s Weight-Loss Franchise Has Been a Massive Winner Under Dave Ricks
|
Jun 21 |
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
|